Clinical trials for Stomach and esophageal cancer
164 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Stomach and esophageal cancer
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Daiichi Sankyo
Early Access
Stomach and esophageal cancer
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
AstraZeneca
Phase 3
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Liver and bile duct cancer
Stomach and esophageal cancer
Small intestine and appendix cancer
#NCT07087054
#2024-519875-24-00
Required histologic types
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3
Stomach and esophageal cancer
#NCT06901531
#2024-519773-19-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3
Stomach and esophageal cancer
#NCT06768164
Required histologic types
Stomach
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery
2 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 3
Pancreas cancer
Stomach and esophageal cancer
#NCT06784752
#2024-518325-15-00
Required histologic types
Stomach
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required SSTR metabolic imaging statuses
SSTR Positive
5 recruiting sites
Novartis
Phase 3
Pancreas cancer
Stomach and esophageal cancer
#NCT05477576
#2023-509334-19-00
Required histologic types
Stomach
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Somatostatin analogs
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
RayzeBio, Inc
Phase 3
Stomach and esophageal cancer
#NCT06731478
#2024-513122-27-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
14 recruiting sites
Daiichi Sankyo
Phase 3
Stomach and esophageal cancer
#NCT06764875
#2024-512583-57-00
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
6 recruiting sites
AstraZeneca
Phase 3
Stomach and esophageal cancer
#NCT06346197
#2023-506291-28-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
7 recruiting sites
Centre Léon Bérard